Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Cancer Research

• Publication date

  1993-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8439955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Local and regional immunotherapy of cancer with interleukin 2

  2005cited by this paper
• Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

  1991cited by this paper
• Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

  1991cited by this paper
• Interleukin 7 induces CD4+ T cell-dependent tumor rejection

  1991cited by this paper
• Human immunodeficiency virus (HIV)-infected tumor xenografts as an in vivo model for antiviral therapy: role of alpha/beta interferon in restriction of tumor growth in nude mice injected with HIV-infected U937 tumor cells

  1991cited by this paper
• Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice

  1991cited by this paper
• Synergistic anti‐tumor effects of combined IL‐1/IFN‐α/β therapy in mice injected with met astatic friend erythroleukemia cells

  1991cited by this paper
• Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer

  1991cited by this paper
• Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.

  1991cited by this paper
• Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.

  1991cited by this paper
• Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases

  1991cited by this paper
• Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2.

  1990cited by this paper
• Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

  1990cited by this paper
• Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4.

  1990cited by this paper
• Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

  1990cited by this paper
• Anti‐tumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases

  1990cited by this paper
• Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

  1990cited by this paper
• Antitumor effects of interferon.

  1989cited by this paper
• Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.

  1989cited by this paper
• Murine interleukin-4 displays potent anti-tumor activity in vivo.

  1989cited by this paper
• Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of friend erythroleukemia cells

  1988cited by this paper
• Studies on the expression of spontaneous and induced interferons in mouse peritoneal macrophages by means of monoclonal antibodies to mouse interferons.

  1987cited by this paper
• Anti‐tumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. IV. Definition of optimal treatment regimens

  1986cited by this paper
• Clinical toxicity of interferons in cancer patients: a review.

  1986cited by this paper
• Biologic and biochemical differences between in vitro and in vivo passaged friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize

  1984cited by this paper
• Biologic and biochemical differences between in vitro and in vivo passaged friend erythroleukemia cells. II. Changes in cell surface glycoproteins associated with a highly malignant phenotype

  1984cited by this paper
• Construction and applications of a highly transmissible murine retrovirus shuttle vector.

  1984cited by this paper
• Structure and expression of cloned murine IFN-alpha genes.

  1983cited by this paper
• Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously

  1983cited by this paper
• Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. I.

  1982cited by this paper
• Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain.

  1982cited by this paper
• The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene.

  1980cited by this paper
• Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo

  1979cited by this paper
• Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection

  1976cited by this paper

• The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

  2021cites this paper
• Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion.

  2019cites this paper
• Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

  2017cites this paper
• Experimental therapies: gene therapies and oncolytic viruses.

  2016cites this paper
• Role of type I interferon in inducing a protective immune response: perspectives for clinical applications.

  2015cites this paper
• Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.

  2011cites this paper
• A Semliki Forest virus vector engineered to express IFNα induces efficient elimination of established tumors

  2011cites this paper
• The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma.

  2010cites this paper
• Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model.

  2010cites this paper
• Interferon: An Unfolding Tale

  2007cites this paper
• Interferon-α and cancer : Mechanisms of action and new perspectives of clinical use

  2007cites this paper
• IFN-alpha and novel strategies of combination therapy for cancer.

  2007cites this paper
• Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.

  2007cites this paper
• IFN‐α and Novel Strategies of Combination Therapy for Cancer

  2007cites this paper
• Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration

  2007cites this paper
• Transduction of murine and human tumors using recombinant adenovirus vectors

  2006cites this paper
• Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients.

  2006cites this paper
• Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon α gene therapy in combination with adoptive chemoimmunotherapy

  2005cites this paper
• Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine.

  2005cites this paper
• Nonviral cytokine gene therapy on an orthotopic bladder cancer model.

  2003cites this paper
• Evaluation of cytokeratin-19 & cytokeratin-20 and interleukin-6 in Egyptian bladder cancer patients.

  2002cites this paper
• DNA vaccine against Friend erythroleukaemia virus.

  2002cites this paper
• Interferon-alpha in tumor immunity and immunotherapy.

  2002cites this paper
• Regression of tumors by IFN-α electroporation gene therapy and analysis of the responsible genes by cDNA array

  2002cites this paper
• Intramuscular electroporation delivery of IFN-α gene therapy for inhibition of tumor growth located at a distant site

  2001cites this paper
• Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models.

  2001cites this paper
• Inoculation of Human Interleukin-17 Gene-Transfected Meth-A Fibrosarcoma Cells Induces T Cell-Dependent Tumor-Specific Immunity in Mice

  2001cites this paper
• Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells

  2001cites this paper
• Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha

  2000cites this paper
• Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.

  2000cites this paper
• Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications.

  2000cites this paper
• InfiltrationOvarian Cancer In Vivo Due to Neutrophil IL-8 Reduced Tumorigenicity of Human

  2000cites this paper
• IL-8 Reduced Tumorigenicity of Human Ovarian Cancer In Vivo Due to Neutrophil Infiltration1

  2000cites this paper
• The use and development of retroviral vectors to deliver cytokine genes for cancer therapy.

  2000cites this paper
• Regulation of neoplastic angiogenesis.

  2000cites this paper
• Critical determinants of neoplastic angiogenesis.

  2000cites this paper
• Plasmides d'interferon alpha, systemes d'administration et procedes de fabrication desdits plasmides

  1999cites this paper
• Treatment of breast cancer with fibroblasts transfected with DNA from breast cancer cells.

  1999cites this paper
• Murine interferon-alpha1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-alpha/beta therapy.

  1999cites this paper
• Murine interferon-α1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-α/β therapy

  1999cites this paper
• CellsTransfected with DNA from Breast Cancer Treatment of Breast Cancer with Fibroblasts

  1999cites this paper
• Regulation of Angiogenesis by the Organ Microenvironment

  1999cites this paper
• Interferon (IFN)-β Gene Transfer into TS/A Adenocarcinoma Cells and Comparison with IFN-α: Differential Effects on Tumorigenicity and Host Response

  1999cites this paper
• A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha.

  1999cites this paper
• Cytokine gene therapy: hopes and pitfalls.

  1999cites this paper
• Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response.

  1999cites this paper
• Interferon (IFN)- b Gene Transfer into TS/A Adenocarcinoma Cells and Comparison with IFN- a Differential Effects on Tumorigenicity and Host Response

  1999cites this paper
• Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer.

  1999cites this paper
• Mouse Melanoma Cells DNASemiallogeneic Fibroblasts Transfected with Resistance to Melanoma in Mice Immunized with

  1998cites this paper
• Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.

  1998cites this paper
• Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

  1998cites this paper
• Immunotherapy against murine leukemia

  1998cites this paper
• Efficacy of B16 Melanoma Cells Exposed In Vitro to Long-Term IFN-α Treatment (B16α Cells) as a Tumor Vaccine in Mice

  1998cites this paper
• Resistance to melanoma in mice immunized with semiallogeneic fibroblasts transfected with DNA from mouse melanoma cells.

  1998cites this paper
• The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice.

  1998cites this paper
• Cytokine gene transfer in cancer therapy

  1998cites this paper
• Cytokine gene transduction into non-immunogeneic murine tumor cells.

  1998cites this paper
• Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16alpha cells) as a tumor vaccine in mice.

  1998cites this paper
• B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16 alpha cells) as activators of tumor immunity in mice.

  1997cites this paper
• EXTRACELLULAR MATRIX REMODELLING IN A MURINE MAMMARY ADENOCARCINOMA TRANSFECTED WITH THE INTERFERON‐ALPHA1 GENE

  1997cites this paper
• B16 Melanoma Cells Exposed In Vitro to Long-Term IFN-α Treatment (B16α Cells) as Activators of Tumor Immunity in Mice

  1997cites this paper
• Cytokine gene transduction in the immunotherapy of cancer.

  1997cites this paper
• Procedes et compositions pour l'administration et l'expression d'acides nucleiques codant l'interferon alpha

  1997cites this paper
• Interferons and Other Cytokines

  1997cites this paper
• Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-α and HSVtk: perspectives for the generation of cancer vaccines

  1997cites this paper
• Tumor immunotherapy by vaccination with cytokine gene transfected cells.

  1997cites this paper
• Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models

  1997cites this paper
• Cytokines in animal models of cancer

  1996cites this paper
• The neglected role of type I interferon in the T-cell response: implications for its clinical use.

  1996cites this paper
• Cytokine gene-modified vaccines in the therapy of cancer.

  1996cites this paper
• Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression.

  1996cites this paper
• Genetic approaches to cancer immunotherapy.

  1996cites this paper
• Transfection of IFNalpha in human glioblastoma cells and tumorigenicity in association with induction of PKR and OAS gene expression.

  1996cites this paper
• Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules.

  1996cites this paper
• The potential applications of gene transfer in the treatment of patients with cancer: a concise review.

  1996cites this paper
• Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin.

  1996cites this paper
• Induction of Immunity Against Leukemia

  1996cites this paper
• Cure of Mice with Established Metastatic Friend Leukemia Cell Tumors by a Combined Therapy with Tumor Cells Expressing Both Interferon-α1 and Herpes Simplex Thymidine Kinase Followed by Ganciclovir

  1996influential citation
• Influence of local cytokines on tumor metastasis: using cytokine gene-transfected tumor cells as experimental models.

  1996cites this paper
• The essential role of endogenous IFN α/β in the anti‐metastatic action of sensitized T lymphocytes in mice injected with friend erythroleukemia cells

  1995cites this paper
• Injection of irradiated b16 melanoma genetically-modified to secrete IFN-alpha causes regression of an established tumor.

  1995cites this paper
• Role of interferons and other cytokines in the regulation of the immune response

  1995cites this paper
• Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.

  1995cites this paper
• Tumor cells cotransfected with interleukin‐7 and B7.1 genes induce CD25 and CD28 on tumor‐infiltrating T lymphocytes and are strong vaccines

  1995cites this paper
• Molecular approaches to cancer immunotherapy.

  1995cites this paper
• Local and Systemic Response of Mice to Interferon-α1 -Transfected Friend Leukemia Cells

  1995cites this paper
• The essential role of endogenous IFN alpha/beta in the anti-metastatic action of sensitized T lymphocytes in mice injected with Friend erythroleukemia cells.

  1995cites this paper
• Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration.

  1995cites this paper
• Increasing tumour immunogenicity by genetic modification.

  1994cites this paper
• Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?

  1994cites this paper
• Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model.

  1994cites this paper
• Neoplastic cells that express low levels of MHC class I determinants escape host immunity.

  1994cites this paper
• Gene Therapy for Cancer

  1994cites this paper
• Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells.

  1994cites this paper
• Cytokine-mediated gene therapy for cancer

  1994cites this paper
• IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.

  1994cites this paper
• Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma.

  1994cites this paper
• Immunization with interleukin‐2‐secreting allogeneic mouse fibroblasts expressing melanoma‐associated antigens prolongs the survival of mice with melanoma

  1993cites this paper
• Mammalian gene studies

  1993cites this paper
• Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma.

  1993cites this paper